ATD Bioseek

 

TIDMATD 
 
RNS Number : 1570T 
Asterand PLC 
23 September 2010 
 

+-------------------------------------+--------------------------------+ 
| For Immediate Release               |              23 September 2010 | 
+-------------------------------------+--------------------------------+ 
 
 
 
 
          Asterand's Subsidiary BioSeek Signs Agreement with Cellzome 
 
   Two Year Deal Provides Cellzome with Access to BioSeek's BioMAP  Platform 
 
Asterand plc (LSE: ATD), a leading provider of human tissue and human 
tissue-based research services to pharmaceutical and biotechnology companies 
engaged in drug discovery research, today announced that its subsidiary BioSeek, 
LLC, a pioneer in the application of predictive human biology to drug discovery, 
has signed a two-year agreement with Cellzome. 
Under the agreement, BioSeek will apply its unique BioMAP  predictive human 
disease models to support and advance Cellzome's discovery projects in the 
treatment of inflammatory diseases. 
 
Oliver Rausch, Vice President Biology at Cellzome , noted: 
"We are delighted to partner with BioSeek for access to their proprietary human 
biology models. The BioMAP  platform will allow us to receive early insight into 
the human pharmacological and toxicological properties of our small molecules, 
enabling us to develop safer and more effective treatments for inflammation." 
Asterand's CEO, Martyn Coombs, commented: 
 
 "We are honoured that Cellzome has chosen BioSeek to support their drug 
discovery and development programmes. Our BioMAP  platform is uniquely suited 
for predicting possible human clinical responses of the small molecules Cellzome 
identifies with its proprietary screening and profiling technologies, 
Kinobeads(TM) and EpisphereTM. Our team looks forward to working with Cellzome 
scientists on the advancement of new innovative treatments for inflammatory 
diseases. We are also delighted with BioSeek's performance since being 
successfully integrated earlier this year and this is clearly demonstrated by 
the Cellzome agreement, the fifth collaboration agreement signed this year." 
 
Contacts: 
 
Asterand plc 
Martyn Coombs, Chief Executive Officer                              Tel: + 44 
(0) 1763 211 600 / 
       + 1 (313) 263-0960 
John Stchur, Chief Financial Officer                                       As 
above 
 
Cellzome 
Oliver Rausch, VP Biology 
Tel: +44 (0)1799 532805 
 
 
Buchanan Communications 
Lisa Baderoon / Mark Court / Isabel Podda                            Tel: +44 
(0) 20 7466 5000 
 
Daniel Stewart & Company plc 
Martin Lampshire 
   Tel: +44 (0) 20 7776 6550 
 
About ASTERAND 
Asterand plc is a leading supplier of high quality human tissue and tissue-based 
services. Our comprehensive approach to human tissue and research services 
offers pharmaceutical, biotech and diagnostic companies the unique opportunity 
to have one company meet all of their human biomaterial needs along the 
continuum of drug discovery and development. Our mission is to accelerate target 
discovery and compound validation and enable pharmaceutical and biotechnology 
companies to take safer and more effective drugs into the market. For more 
information about Asterand or BioSeek, go to www.asterand.com. 
About Cellzome 
Cellzome is a privately-owned drug discovery and development company, and a 
leader in the use of chemical proteomics technologies to identify a new 
generation of drug candidates for the treatment of inflammatory diseases. Its 
pipeline of small-molecule therapeutics is driven by Kinobeads(TM), a 
proprietary technology for screening and profiling kinases in their 
physiological context. We have developed a new technology, called Episphere(TM) 
to address epigenetic targets in disease-specific protein complexes. The 
Company's goal is to identify oral therapeutics for inflammatory diseases such 
as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease. 
 
Cellzome has two strategic alliances with GSK to discover and develop drugs to 
treat inflammatory diseases, the first in the field of kinase-targeted 
therapeutics and the second in the field of epigenetics. 
 
Cellzome's holding company is domiciled in the US and it employs about 90 people 
at its two R&D laboratories in Cambridge, UK and Heidelberg, Germany. To learn 
more about Cellzome, please visit the website: www.cellzome.com. 
 
This information is provided by RNS 
            The company news service from the London Stock Exchange 
   END 
 
 AGREANNAAFSEEFF 
 

Bioseek (LSE:ATD)
Historical Stock Chart
From Sep 2024 to Oct 2024

Bioseek (LSE:ATD)
Historical Stock Chart
From Oct 2023 to Oct 2024